Thursday, 15 October 2026European Markets

ZAPTEC Stock 11.06% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with ZAPTEC (ZAP.OL) rising 11.06% to kr38.16 on Friday, following the last session's upward trend. Oslo Børs Benchmark Index_GI rose 0.75% to kr1,193.57, after four sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.

ZAPTEC's last close was kr34.36, 28.09% below its 52-week high of kr47.78.

About ZAPTEC

Zaptec AS engages in the development and sale of chargers, charging systems, and services for electric car charging in Norway and rest of Europe. It offers Zaptec Go, a 22KW charger; Zaptec Pro, a charging station for parking spaces in housing cooperatives and co-ownership properties, companies, and newbuilds; and charging columns for outdoor installations. The company also provides Zaptec Portal, a charging infrastructure that monitors, balances, and optimizes the load between the various charging stations; and Zaptec APM, which measures the power consumption for the building and allocates power to EV charging. It provides charging solutions for homes, multi-family houses, public charging facilities, businesses, and real estate developers. The company was incorporated in 2012 and is based in Stavanger, Norway.

Earnings Per Share

As for profitability, ZAPTEC has a trailing twelve months EPS of kr0.24.

PE Ratio

ZAPTEC has a trailing twelve months price to earnings ratio of 161.01. Meaning, the purchaser of the share is investing kr161.01 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.97%.

More news about ZAPTEC (ZAP.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com